Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, P.R. China.
Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, UK.
Oncol Rep. 2017 Aug;38(2):886-898. doi: 10.3892/or.2017.5738. Epub 2017 Jun 21.
The aims of the present study were to determine whether the changes in density and location of CD68-positive and CD206-positive macrophages contribute to progression of hepatocellular carcinoma (HCC) and to evaluate prognostic values of these cells in post-surgical patients. A retrospective study involving 268 HCC patients was conducted. CD68-positive and CD206-positive macrophage infiltration in HCC tissues and adjacent tissues was examined by immunohistochemistry (IHC) and the relationship between the clinicopathological features and prognosis was analyzed. Receiver operating characteristics (ROC) curve was used to calculate diagnostic accuracy. There was an increase in CD68-positive and CD206-positive macrophage infiltration in adjacent tumor tissues compared with tumor tissues. ROC curve identified their optimal diagnostic cut-off values. The survival analysis showed that increased CD68 expression in adjacent tissues conferred superior overall survival (OS) and disease-free survival (DFS), while increase of CD206 in tumor yielded inferior OS and DFS. Cox regression analysis suggested both CD68-positive macrophages in adjacent area and intratumor CD206-positive macrophages as independent prognostic biomarkers for post-surgical HCC patients. Finally, a combination of CD68/CD206 and HBV-positive further improved prognostic stratification, especially in DFS. These results provide the first evidence for region- and subset-dependent involvement of CD68 and CD206 cells in HCC progression. A combination of CD68/CD206 density and HBV-positivity improves further predictive value for post-operative recurrence of HCC. Quantification of CD68/CD206 macrophages and their distribution can be exploited for better postsurgical management of HCC patients. These findings provide a basis for developing novel treatment strategies aimed at re-educating macrophages in tumor microenvironment.
本研究旨在确定 CD68 阳性和 CD206 阳性巨噬细胞的密度和位置变化是否有助于肝细胞癌(HCC)的进展,并评估这些细胞在术后患者中的预后价值。进行了一项涉及 268 例 HCC 患者的回顾性研究。通过免疫组织化学(IHC)检查 HCC 组织和相邻组织中 CD68 阳性和 CD206 阳性巨噬细胞的浸润情况,并分析其与临床病理特征和预后的关系。采用受试者工作特征(ROC)曲线计算诊断准确性。与肿瘤组织相比,相邻肿瘤组织中 CD68 阳性和 CD206 阳性巨噬细胞浸润增加。ROC 曲线确定了它们的最佳诊断截止值。生存分析显示,相邻组织中 CD68 表达增加可改善总生存期(OS)和无病生存期(DFS),而肿瘤中 CD206 增加则导致 OS 和 DFS 降低。Cox 回归分析表明,相邻区域的 CD68 阳性巨噬细胞和肿瘤内的 CD206 阳性巨噬细胞均是术后 HCC 患者的独立预后生物标志物。最后,CD68/CD206 和 HBV 阳性的组合进一步改善了预后分层,尤其是在 DFS 方面。这些结果首次提供了 CD68 和 CD206 细胞在 HCC 进展中区域和亚群依赖性参与的证据。CD68/CD206 密度和 HBV 阳性的组合进一步提高了 HCC 术后复发的预测价值。定量检测 CD68/CD206 巨噬细胞及其分布可用于改善 HCC 患者的术后管理。这些发现为开发旨在重新教育肿瘤微环境中巨噬细胞的新型治疗策略提供了依据。